Eximmium Biotechnologies

Eximmium Biotechnologies is a clinical-stage biotechnology company specializing in the discovery and development of first-in-class antibody therapeutics for oncology. Founded as a spin-off from the Helmholtz Zentrum München, the company utilizes a proprietary platform based on extracellular vesicles (EVs) to identify novel, tumor-specific surface antigens that were previously considered intracellular. Its lead programs include a radio-immunoconjugate targeting Carbonic anhydrase XII for glioblastoma and novel antibodies targeting SRRM2 for multiple myeloma and other solid tumors. Eximmium operates globally with sites in Munich, Singapore, and China, focusing on high-translational potential therapies and companion diagnostics. The company is a member of the BioIP Holdings group and maintains strong academic ties to German research institutions.